One of the benefits of the increasing adoption of robotics and automation for fill-finish processing is that with growth comes standardization and accessibility. There has been a confluence of focus and interest in small-scale aseptic processing solutions, preceded by market trends in drug discovery, patient-centered medicine, and compounded pharmaceutical products. Other trends like decentralized manufacturing, point-of-care manufacturing, and advancements in modular solutions for fill-finish have coincided as avenues to address these growing segments of the industry.  With advanced automated technology more available, the pharmaceutical industry is approaching the drug development lifecycle more holistically, as automated and data solutions address key operational friction points in areas like project scaling, validation, and technology transfer.

Still, professionals in drug research and development or direct-to-patient applications like compound pharmacies, may hesitate when deciding whether or not to adopt advanced solutions. Is it cost-effective for smaller operations, startups, and new/potential products in the early stage of development? Does the design of the automation lend itself to ease of training, or is there a steep learning curve? And what advantages do robotics and automation offer for both the process and operator over manual setups?